Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telinavir SCHEMBL4432111 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL29450575 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL2773923 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL31107105 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL6361258 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL623164 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL5689588 | 0.95 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL6224163 | 0.95 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL8562300 | 0.93 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL6225032 | 0.93 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4CACNA1FABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1733725-B2 | Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water | ABBOTT LAB (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2269591-A2 | Improved pharmaceutical formulations | Abbott Laboratories (US) | 2011-01-05 | — | — | EP | claimed |
| EP-1733725-B1 | Farmaceutical formulations comprising at least one HIV protease inhibiting compound | ABBOTT LAB (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1248600-B1 | IMPROVED HIV PROTEASE INHIBITORS PHARMACEUTICAL FORMULATIONS | ABBOTT LAB (US) | 2008-05-14 | — | — | EP | claimed |
| US-20070032435-A1 | Pharmaceutical formulations | ABBOTT LABORATORIES | 2007-02-08 | — | — | US | claimed |
| EP-1733725-A1 | Farmaceutical formulations comprising at least one HIV protease inhibiting compound | Abbott Laboratories (US) | 2006-12-20 | — | — | EP | claimed |
| US-20050048112-A1 | Solid pharmaceutical dosage form | ABBOTT LABORATORIES | 2005-03-03 | — | — | US | claimed |
| EP-1227797-B1 | SOLID DISPERSION PHARMACEUTICAL FORMULATIONS | ABBOTT LAB (US) | 2005-01-12 | — | — | EP | claimed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | claimed |
| EP-1295874-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2003-03-26 | — | — | EP | claimed |
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | claimed |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2002-01-10 | — | — | US | claimed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | claimed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | claimed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | claimed |
| US-5610193-A | TREATMENT OF AIDS, HIV, IMPROVED ORAL BIOAVAILABILITY | ABBOTT LABORATORIES (US) | 1997-03-11 | — | — | US | claimed |
| US-5484801-A | Pharmaceutical composition for inhibiting HIV protease | ABBOTT LABORATORIES (US) | 1996-01-16 | — | — | US | claimed |
| EP-2283844-B1 | A solid pharmaceutical dosage formulation comprising lopinavir | ABBVIE INC (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032435-A1 | Pharmaceutical formulations | TMPRSS15, PRSS3, PRSS8 | CYP3A4 201/4885ABCC3 1969/4885ABCC4 3199/4885 |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | CYP3A4 1600/4885ABCC3 2311/4885ABCC4 2547/4885 |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | CYP3A4 1600/4885ABCC3 2311/4885ABCC4 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.